| Name | Title | Contact Details |
|---|
Avaxia is a leader in the growing field of gut-targeted therapeutics — orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal tract. Avaxia’s lead clinical candidate, AVX-470, is an oral anti-TNF antibody for inflammatory bowel disease. This transformative product offers potentially improved safety and efficacy over existing anti-TNF therapies by focusing immune suppression only where needed in the diseased gut. Avaxia plans to use its gut-targeted antibody platform to develop therapeutics to address many other serious diseases such as type 2 diabetes, celiac disease, GI acute radiation syndrome and oral mucositis.
Vista Community Clinic is a Vista, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Bard Access Systems is a Salt Lake City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Greater Roslindale Medical and Dental Center is a Roslindale, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cal eConnect serves as the State's governance entity for health information exchange. As such, Cal eConnect is responsible for meeting requirements set forth in the State's grant agreement with the federal Office of the National Coordinator for Health Information Technology (ONC).